Tactile Systems Technology, Inc. Reports Third Quarter 2026 Financial Results
Key Highlights
- ➤Q3 revenue $91.9 million, up 7% year-over-year
- ➤Lymphedema revenue $81.8 million, up 13% year-over-year
- ➤Q3 net income fell to $7.2 million from $8.2 million
- ➤2026 Adjusted EBITDA guidance raised to $50 million-$52 million
- ➤FDA cleared expanded LymphaTech 3D Scanner indication
Expert Statements
Sheri Dodd, Chief Executive Officer of Tactile Medical
“Our results underscore the strength and durability of our core lymphedema business, which delivered its fifth consecutive quarter of double-digit year-over-year revenue growth, while gross margin expanded for the 12(th) consecutive quarter.”
Sheri Dodd, Chief Executive Officer of Tactile Medical
“As a market leader in both the basic and advanced pneumatic compression categories, we see substantial opportunity ahead in a market that remains significantly underpenetrated.”
Sheri Dodd, Chief Executive Officer of Tactile Medical
“We are positioned to capture that opportunity through three connected strategic priorities: expanding access to care, creating value across the patient journey, and broadening treatment options. Together, we believe these priorities provide a clear path toward sustaining above-market lymphedema growth, driving operating leverage, and delivering shareholder value over the long term.”
MINNEAPOLIS, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chronic disorders, today reported financial results for the third quarter ended September 30, 2026.
Third Quarter 2026 Summary and Recent Business Highlights: * Total revenue increased 7% year-over-year to $91.9 million; revenue from our lymphedema product line increased 13% year-over-year to $81.8 million * Gross margin expanded to 77% from 76% in Q3 2025 * Net income decreased to $7.2 million from $8.2 million in Q3 2025 * Adjusted EBITDA was $14.3 million, compared to $14.4 million in Q3 2025 * Received FDA 510(k) clearance expanding the LymphaTech 3D Scanner’s indication to aid in the assessment of lymphedema * Submitted a 510(k) application to the FDA for Flexitouch® Pro, featuring enhancements to the Company’s advanced pneumatic compression system * Appointed Steve Kiewiet as Chief Operating Officer, with responsibility for order operations and patient services * Repurchased $6.2 million of stock under the Company’s share repurchase program “Our results underscore the strength and durability of our core lymphedema business, which delivered its fifth consecutive quarter of double-digit year-over-year revenue growth, while gross margin expanded for the 12(th) consecutive quarter,” said Sheri Dodd, Chief Executive Officer of Tactile Medical. “As a market leader in both the basic and advanced pneumatic compression categories, we see substantial opportunity ahead in a market that remains significantly underpenetrated.”
Get started
Create a free account to read the full story.